Clinical trials: Locally Advanced Colorectal Cancer
Rectal Cancer, Radiation Oncology
Chemotherapy and Tislelizumab With Split-course HFRT for Locally Advanced Rectal Cancer
The question of how to administer adequate chemotherapy and immunotherapy to synchronise hypofraction radiotherapy （HFRT） treatment strategy to maximise the benefits of neoadjuvant therapy for the improved prognosis of patients…
- Trial name
- NCT05176964
- Testing
- split-course HFRT, CAPOX chemotherapy, Tislelizumab
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Fujian Medical University Union Hospital
Colon Adenocarcinoma, Rectal Adenocarcinoma
A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)
Researchers are looking for other ways to treat locally advanced or metastatic colorectal cancer (mCRC) that is unresectable and has a gene mutation called KRAS G12C.
- Trial name
- NCT06997497
- Testing
- Calderasib, Oxaliplatin, Leucovorin/levofolinate calcium
- Where
- 244 sites in United States, Argentina and 27 more
- Volunteers
- 477 people
- Sponsor
- Merck Sharp & Dohme LLC
Malignant Neoplasm of Colorectum
Radical Colorectal Resection and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Locally Advanced Colorectal Cancer
The efficacy of HIPEC in prevention of local recurrence, distant metastasis or peritoneal metastasis in locally advanced colorectal cancer is not definite.
- Trial name
- NCT02830139
- Testing
- Hyperthermic intraperitoneal chemotherapy (HIPEC), Radical colorectal resection, Oxaliplatin , Capecitabine
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Wuhan University
Rectal Cancer
Neoadjuvant Chemoradiotherapy Combined With Immunotherapy and Anti-angiogenesis in Treating Locally Advanced Rectal Cancer
This is a multicenter, prospective, randomized phase II trial designed to evaluate the efficacy and safety of short-course neoadjuvant chemoradiotherapy combined with the PD-1 monoclonal antibody serplulimab and the…
- Trial name
- NCT07134218
- Testing
- serplulimab、bevacizumab, neoadjuvant chemoradiation therapy
- Where
- China
- Volunteers
- 180 people
- Sponsor
- Changhai Hospital
Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum
Combination Chemotherapy and Bevacizumab in Treating Patients With Locally Advanced, Metastatic, or Recurrent Colorectal Cancer
Drugs used in chemotherapy, such as oxaliplatin, leucovorin, fluorouracil, and capecitabine, work in different ways to stop cancer cells from dividing so they stop growing or die.
- Conditions
- Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum, Recurrent Colon Cancer, Recurrent Rectal Cancer
- Trial name
- NCT00070122
- Testing
- oxaliplatin, leucovorin calcium, capecitabine
- Where
- United States
- Volunteers
- 2,200 people
- Sponsor
- National Cancer Institute (NCI)
Rectal Neoplasms, Rectal Cancer, Adenocarcinoma
SCRT + Fruquintinib + Tislelizumab + CAPOX Versus SCRT + Tislelizumab + CAPOX as Neoadjuvant Therapy for Locally Advanced Low Rectal Cancer
The goal of this randomized controlled clinical trial is to learn if adding fruquintinib to short-course radiotherapy, tislelizumab, and CAPOX can improve neoadjuvant treatment response and is safe for adults with locally…
- Trial name
- TRIP-FAST (NCT07888309)
- Testing
- Short-Course Radiotherapy, Fruquintinib, Tislelizumab
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Ruijin Hospital
Colorectal Cancer Stage II, Colorectal Cancer Stage III
Pd1 Antibody Sintilimab ± Chemoradiotherapy for Locally Advanced Rectal Cancer
In this study, participants with locally advanced rectal cancer patients will be treated according to MMR/MSI status. There will be two cohorts in this study: Cohort A and Cohort B.
- Trial name
- NCT04304209
- Testing
- Oxaliplatin, Capecitabine, Sintilimab
- Where
- China
- Volunteers
- 195 people
- Sponsor
- Sun Yat-sen University
High-risk Locally Advanced Colorectal Cancer, Neoadjuvant Chemotherapy
FOLFOXIRI for Neoadjuvant Treatment of High-risk Locally Advanced Colorectal Cancer
The main cause of recurrence after surgical treatment of colorectal cancer is distant metastasis. Neoadjuvant chemotherapy has potential benefits of improving the effectiveness of chemotherapy.
- Conditions
- High-risk Locally Advanced Colorectal Cancer, Neoadjuvant Chemotherapy, FOLFOXIRI Regimen
- Trial name
- NCT05018182
- Testing
- Oxaliplatin, Irinotecan, Folinic Acid
- Where
- China
- Volunteers
- 69 people
- Sponsor
- West China Hospital
Metastatic Breast Cancer or Metastatic Colorectal Cancer
A Bioequivalence Study of Capecitabine Tablets
1. purpose: To conduct the relative bioavalability study of Capecitabine tablets 500 mg (Jiangsu Chia-Tai Tianqing Pharmacy Co. Ltd.) versus XELODA® 500 mg tablets (Manufactured by Roche Pharma AG) 2.
- Trial name
- NCT01846650
- Testing
- Capecitabine tablets, XELODA
- Where
- China
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Locally Advanced Colon Cancer, pMMR
Chemotherapy Combined With or Without Short-Course Radiotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for High-Risk Locally Advanced Colon Cancer With pMMR/MSS
Locally advanced colon cancer, particularly T4 disease or colon cancer with bulky nodes, carries a poor prognosis and limited efficacy with neoadjuvant chemotherapy.
- Trial name
- TORCH-C2 (NCT07877597)
- Testing
- short-course radiotherapy, Serplulimab, CapOx(Capecitabine+ Oxaliplatin)
- Where
- China
- Volunteers
- 480 people
- Sponsor
- Fudan University
Gastric Cancer, Hepatocellular Carcinoma
Personalized DC Vaccine for Postoperative Cancer
The study is aimed to the test efficacy and safety of neoantigen-primed dendritic cell (DC) cell vaccine therapy for postoperative locally advanced gastric cancer, hepatocellular carcinoma, lung cancer and colorectal cancer, and…
- Conditions
- Gastric Cancer, Hepatocellular Carcinoma, Non-Small-Cell Lung Cancer, Colon Rectal Cancer
- Trial name
- NCT04147078
- Testing
- DC vaccine subcutaneous administration
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Sichuan University
Rectal Cancer, Adenocarcinoma, Rectal Cancer Stage II
"Oncologic Results and Risk Factors for Recurrence in Patients With Locally Advanced Rectal Cancer and Pathologic Complete Response After Neoadjuvant Treatment. Results From an Observational Retrospective Multicenter Long-term Follow-up Study".
Pathologic complete response (pCR) after multimodal treatment for locally advanced rectal cancer (LARC) patients is considered as the gold-standard of treatment success as it is associated to privileged oncologic outcome.
- Conditions
- Rectal Cancer, Adenocarcinoma, Rectal Cancer Stage II, Rectal Cancer Stage III, Distant Metastasis
- Trial name
- NCT05495308
- Testing
- neoadjuvant treatment
- Where
- Spain
- Volunteers
- 4 people
- Sponsor
- Hospital San Carlos, Madrid
Colorectal Cancer Metastatic
Isunakinra Alone and in Combination With Pembrolizumab in Patients With Colorectal Cancer (MSS)
This study will enroll patients with colorectal cancer that is locally advanced or metastatic. The tumor must be microsatellite stable (MSS), have a tumor mutational burden that is high (TMB-H) and be kras mutated.
- Trial name
- NCT06634875
- Testing
- isunakinra
- Where
- 3 sites in United States
- Volunteers
- 20 people
- Sponsor
- Buzzard Pharmaceuticals
Locally Advanced Rectal Cancer, Older People
Efficacy and Safety of Conventional Neoadjuvant Therapy Versus Total Neoadjuvant Therapy in Older Patients With Locally Advanced Rectal Cancer
The SHAPERS study is a multicentre, open-label, randomised, pragmatic clinical trial, comparing standard-of-care neoadjuvant treatment options for older (i.e., ≥70 years) subjects with high-risk stage II and stage III rectal…
- Trial name
- SHAPERS (NCT06052332)
- Testing
- Short course radiotherapy, Adjuvant chemotherapy (optional), Total mesorectal excision
- Where
- 19 sites in Belgium
- Volunteers
- 230 people
- Sponsor
- Jules Bordet Institute
Colon Rectal Cancer
Immunotherapy In Locally Advanced Rectal Cancer
Preoperative CTRT is considered the standard of care in the management of LARC. Preoperative CTRT approach results in significant tumor downstaging and local control with a complete pathological response rate of about 15% even if…
- Trial name
- AVANA (NCT03854799)
- Testing
- Avelumab, Capecitabine, EXTERNAL---BEAM IRRADIATION 50.4 GY
- Where
- Italy
- Volunteers
- 101 people
- Sponsor
- Gruppo Oncologico del Nord-Ovest
Locally Advanced Rectal Cancer
Development of a Genome-based Platform for Personalized Treatment in Locally Advanced Rectal Cancer Patients
This study is aimed to develop a genome-based platform to predict patients who can achieve pathologic complete response after neoadjuvant treatment in locally advanced rectal cancer.
- Trial name
- NCT04738214
- Testing
- Neoadjuvant CCRT+operation +/- adjuvant treatment
- Where
- South Korea
- Volunteers
- 39 people
- Sponsor
- Yonsei University
Rectal Cancer
Locally Advanced Rectal Cancer - Exfoliated Peritoneal Tumor Cells
During the course of tumor growth and possibly by manipulation during the surgical procedure, cells from rectal tumors may be shed into the peritoneal cavity.
- Trial name
- LARC-EX (NCT02113384)
- Testing
- Observational study.
- Where
- Norway
- Volunteers
- 231 people
- Sponsor
- Oslo University Hospital
Rectal Cancer
Induction Chemotherapy,Radiochemotherapy, Consolidation Chemotherapy in Preoperative Treatment of Rectal Cancer
The use of capecitabine based preoperative chemoradiation and adjuvant chemotherapy is standard treatment of locally advanced rectal cancer.
- Trial name
- NCT01489332
- Testing
- intensified preoperative chemotherapy
- Where
- Slovenia
- Volunteers
- 60 people
- Sponsor
- Institute of Oncology Ljubljana
Rectal Cancer
Preoperative Radiotherapy and Chemotherapy in Patients With Locally Advanced Rectal Cancer
The aims of the trial are (1) to determine the tolerability rate in the setting of a multi-centre study and (2) to determine secondary tolerability endpoints, toxicity rates and complete pathologic response rate in patients with…
- Trial name
- PROArCT (NCT01013805)
- Testing
- External Beam Radiotherapy, Oxaliplatin, Fluorouracil
- Where
- Australia
- Volunteers
- 41 people
- Sponsor
- Trans Tasman Radiation Oncology Group
Rectal Cancer
Neoadjuvant Chemoradiotherapy Plus Sintilimab for Intermediate/High Immunoscore Locally Advanced Rectal Cancer
Immunoscore has been reported to be superior to microsatellite instability staging in predicting the disease-specific recurrence and survival for patients with colorectal cancer.
- Trial name
- SILAR (NCT05450029)
- Testing
- Sintilimab
- Where
- China
- Volunteers
- 51 people
- Sponsor
- Yanhong Deng